Hims & Hers Health (NYSE: HIMS) delivered a genuine revenue surprise on Monday, reporting second-quarter revenue of $753.2 million — nearly $53 million above analyst consensus — but the company swung ...
Target Price (Mid): ~$27Street Target: ~$31Potential Total Return: ~(13%)Annualized IRR: ~(3%) / yearWhat Happened?Hims & ...
The June closing of the Eucalyptus acquisition transformed Hims & Hers Health (HIMS) into what the company now calls a global consumer health platform. Bears may be overlooking this shift. Investors ...
Hims & Hers Health is rated a buy, with a fair value estimate of $41 per share versus the current $29.81. Read more on HIMS ...
Suppose improving growth and profitability allow investors to value the company at 2.5x expected 2027 sales. Applying that multiple to the $3.99 billion revenue estimate produces a market ...
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates in healthcare-adjacent markets by delivering access to clinical care and wellness services through a digital, ...
The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against Hims & Hers Health, Inc. ("Hims ...
Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, ...
Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities ...
Hims & Hers Health (HIMS-4.46%), the consumer-focused telehealth platform, closed Tuesday at $29.76, down 4.03%. The stock declined during the regular session after Amazon (AMZN-1.87%) launched a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results